VGX-1027 (GIT 27)

VGX-1027 is a small potent nitric oxide-donating compound with potent immunomodulatory properties. VGX-1027, in microarray analysis, modulates the expression of genes that involved in immune activation and the antigen processing and presentation in response to lipopolysaccharide (LPS) stimulation. VGX-1027 is a TLR4 inhibitor. VGX-1027 is a TLR4 and TLR2/6 signaling pathway modulator. In CD4+CD25− T cells, VGX-1027 inhibited cell proliferation induced by enterobacterial antigen.

Synonyms:

GIT 27;

3-phenyl-4,5-dihydro-5-isoxazoleacetic acid;

4,5-DIHYDRO-3-PHENYL-5-ISOXAZOLEACETIC ACID;

Immunology & Inflammation related Inhibitors Related Prodcuts:

Pimecrolimus; Cyclosporin A; Bestatin; GI254023X; Bindarit; TAPI-1; Avadomide; Thymopentin; Pranlukast; Laquinimod; Y-320; Imiquimod; Levamisole hydrochloride; Halcinonide; Sodium gualenate; Aceclofenac; Fenoprofen calcium; Pidotimod; Etofenamate; Tenoxicam

[1]. Stosic-Grujicic S, et al. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multipl

[2]. Stojanovic I, et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin Immuno